Billing and Coding: MolDX: Germline Testing for use of PARP inhibitors (A55294) - R10 - Effective July 28, 2022

This coverage article has been revised and published for notice under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (HI and Territories), and 01312 (NV).

Effective Date: July 28, 2022

Summary of Article Changes: Under Article Text revised typographical error: The patient does not meet germline testing requirements per existing guidelines or standards of care outlined in policy L38966 requiring more comprehensive testing from L38966 to L38972.

Visit the Noridian Medicare Coverage Articles webpage to view the complete listing of coverage articles and/or access the Active, Future, or Retired articles available in the CMS MCD.

Last Updated Jul 07 , 2023